Mitarbeiter: 42 (2023.0)Rechtsform: SCA (commandite par actions)Größe: GEGründungsdatum: 1986-07-11 (39 Jahre)Status: AktivBranche: Fabrication de préparations pharmaceutiquesStandort: SAINT-AMAND-LES-EAUX (59230), Nord
GLAXOSMITHKLINE BIOLOGICALS : revenue, balance sheet and financial ratios
GLAXOSMITHKLINE BIOLOGICALS is a French company
founded 39 years ago,
specialized in the sector Fabrication de préparations pharmaceutiques.
Based in SAINT-AMAND-LES-EAUX (59230),
this company of category GE
shows in 2024 a revenue of 174.4 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
In 2024, GLAXOSMITHKLINE BIOLOGICALS achieves revenue of 174.4 M€. Revenue is growing positively over 9 years (CAGR: +2.2%). Slight decline of -2% vs 2023. After deducting consumption (6.6 M€), gross margin stands at 167.7 M€, i.e. a rate of 96%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 41.6 M€, representing 23.9% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 12.8 M€, i.e. 7.4% of revenue. This profit can be retained or distributed to shareholders.
Umsatz (2024)
?
Umsatz
Definition
Gesamtbetrag der Verkäufe von Waren und Dienstleistungen des Unternehmens.
Formel
Warenverkäufe + Verkaufte Produktion
174 353 823 €
Bruttomarge (2024)
?
Bruttomarge
Definition
Differenz zwischen Umsatz und Wareneinsatz.
Formel
Umsatz - Wareneinsatz
167 735 015 €
EBITDA (2024)
?
EBITDA (Betriebsergebnis vor Abschreibungen)
Definition
Ressource générée par l'activité courante, avant amortissements et charges financières.
Formel
Wertschöpfung - Personalkosten - Steuern
Interpretation
Positiv = rentable Tätigkeit
41 596 256 €
EBIT (2024)
?
EBIT (Betriebsergebnis)
Definition
Betriebsergebnis, einschließlich Abschreibungen und Rückstellungen.
Formel
EBITDA - Abschreibungen und Rückstellungen + Auflösungen
16 110 695 €
Nettoergebnis (2024)
?
Nettoergebnis
Definition
Bénéfice ou perte après toutes les charges, y compris impôts et éléments exceptionnels.
Le compte de résultat détaillé n'est pas disponible pour cette entreprise (liasse simplifiée ou données confidentielles).
Évolution graphique
Anzeigen :
Visualisierung erstellt mit numbers.finance Sources : INPI & BCE - Anpassungen : Ministère de l'Économie
Aktiva
Chargement des données...
Poste
Brutto
Abschr.
Netto
%
Entwicklung
Données de bilan actif non disponibles pour cette entreprise
Passiva
Chargement des données...
Poste
Jahr
%
Entwicklung
Données de bilan passif non disponibles pour cette entreprise
Solvenz- und Verschuldungskennzahlen
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 79%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 22.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
Verschuldungsgrad (2024)
?
Verschuldungsgrad
Definition
Misst das Verhältnis von Schulden zu Eigenkapital.
Formel
(Finanzschulden / Eigenkapital) x 100
Interpretation
< 50% : Faible 50-100% : Moderat > 100% : Hoch
0.0%
Finanzielle Autonomie (2024)
?
Finanzielle Autonomie
Definition
Anteil des Eigenkapitals an der Gesamtfinanzierung.
Entwicklung der Solvenzkennzahlen GLAXOSMITHKLINE BIOLOGICALS
Visualisierung erstellt mit numbers.finance Sources : INPI & BCE - Anpassungen : Ministère de l'Économie
Kennzahl
2016
2017
2018
2019
2020
2021
2022
2023
2024
Verschuldungsgrad
43.642
20.838
4.66
0.0
0.0
0.0
0.0
0.0
0.0
Finanzielle Autonomie
64.894
75.073
85.093
87.508
86.219
87.149
86.466
77.587
79.175
Rückzahlungsfähigkeit
2.025
0.987
0.214
0.0
0.0
0.0
0.0
0.0
0.0
Cashflow / Umsatz
36.454%
35.229%
36.058%
35.065%
31.299%
29.839%
28.271%
22.99%
21.961%
Positionnement sectoriel
Debt ratio
0.02024
2022
2023
2024
Q1: 0.0
Méd: 5.92
Q3: 43.75
Excellent
In 2024, the debt ratio of GLAXOSMITHKLINE BIOLOGICALS (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
79.17%2024
2022
2023
2024
Q1: 28.05%
Méd: 51.52%
Q3: 72.2%
Excellent-7 pts über 3 Jahre
In 2024, the financial autonomy of GLAXOSMITHKLINE BIOLOGICALS (79.2%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
0.0 years2024
2022
2023
2024
Q1: 0.0 years
Méd: 0.01 years
Q3: 1.74 years
Excellent
In 2024, the repayment capacity of GLAXOSMITHKLINE BIOLOGICALS (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquiditätskennzahlen
The liquidity ratio (= Current assets / Current liabilities) stands at 182.26. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.1x. Danger: operating income does not cover interest charges, unsustainable situation.
Liquiditätsquote (2024)
?
Liquiditätsquote
Definition
Fähigkeit, kurzfristige Schulden mit dem Umlaufvermögen zu decken.
Formel
Umlaufvermögen / Kurzfristige Verbindlichkeiten
Interpretation
> 1.5 : Sehr gut 1-1.5 : Angemessen < 1 : Risque de liquidité
182.265
Zinsdeckung (2024)
?
Zinsdeckung
Definition
Fähigkeit, Zinsaufwendungen mit dem Betriebsergebnis zu decken.
Entwicklung der Liquiditätskennzahlen GLAXOSMITHKLINE BIOLOGICALS
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Kennzahl
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquiditätsquote
128.757
95.004
119.989
246.218
363.904
440.117
452.108
168.336
182.265
Zinsdeckung
8.054
4.737
1.764
0.117
0.044
0.075
0.102
0.177
0.136
Positionnement sectoriel
Liquidity ratio
182.262024
2022
2023
2024
Q1: 120.09
Méd: 209.86
Q3: 363.93
Average-33 pts über 3 Jahre
In 2024, the liquidity ratio of GLAXOSMITHKLINE BIOLOGICALS (182.26) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
0.14x2024
2022
2023
2024
Q1: 0.0x
Méd: 1.78x
Q3: 10.15x
Average
In 2024, the interest coverage of GLAXOSMITHKLINE BIOLOGICALS (0.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Umlaufvermögensbedarf und Zahlungsfristen
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 23 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 95 days. Excellent situation: suppliers finance 72 days of the operating cycle (retail model). Inventory turnover is 30 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 109 days of revenue, i.e. 52.7 M€ to permanently finance. Over 2016-2024, WCR increased by +248%, requiring additional financing.
Operatives Working Capital (2024)
?
Operatives Working Capital
Definition
Besoin de financement généré par le cycle d'exploitation (stocks + créances - dettes fournisseurs).
(Lieferantenverbindlichkeiten / Einkäufe inkl. MwSt.) x 360
Interpretation
Je länger die Frist, desto besser für die Liquidität
95 j
Lagerumschlag (2024)
?
Lagerumschlag (Tage)
Definition
Durchschnittliche Lagerdauer für Waren oder Materialien.
Formel
(Vorräte / Einkaufskosten) x 360
Interpretation
Je niedriger das Verhältnis, desto schneller der Umschlag
30 j
Working Capital in Umsatztagen (2024)
?
Working Capital in Umsatztagen
Definition
Drückt den Betriebskapitalbedarf in Umsatztagen aus.
Formel
(BFR exploitation / CA) x 360
Interpretation
Je weniger Tage, desto besser das Working Capital Management
109 j
Entwicklung des Working Capital und der Zahlungsfristen GLAXOSMITHKLINE BIOLOGICALS
Visualisierung erstellt mit numbers.finance Sources : INPI & BCE - Anpassungen : Ministère de l'Économie
Kennzahl
2016
2017
2018
2019
2020
2021
2022
2023
2024
BFR d'exploitation
15 151 650 €
8 612 675 €
12 462 335 €
48 182 032 €
93 285 496 €
125 453 637 €
151 123 723 €
49 486 915 €
52 656 598 €
Lagerumschlag (Tage)
23
23
24
25
24
25
25
26
30
Crédit clients (jours)
32
25
24
26
26
28
25
29
23
Crédit fournisseurs (jours)
94
93
73
75
93
93
101
91
95
Positionnement de GLAXOSMITHKLINE BIOLOGICALS dans son secteur
Vergleich mit der Branche Fabrication de préparations pharmaceutiques
Bewertungsschätzung
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions).
This range of 2 559 987€ to 7 868 401€ is provided for information purposes only and requires in-depth analysis to be confirmed.
Estimated enterprise value2024
Indicative
2559k€5779k€7868k€
5 779 707 €Range: 2 559 987€ - 7 868 401€
NAF 5 all-time
How is this estimate calculated?
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Fabrication de préparations pharmaceutiques)
Compare GLAXOSMITHKLINE BIOLOGICALS with other companies in the same sector:
Frequently asked questions about GLAXOSMITHKLINE BIOLOGICALS
What is the revenue of GLAXOSMITHKLINE BIOLOGICALS ?
The revenue of GLAXOSMITHKLINE BIOLOGICALS in 2024 is 174.4 M€.
Is GLAXOSMITHKLINE BIOLOGICALS profitable?
Yes, GLAXOSMITHKLINE BIOLOGICALS generated a net profit of 12.8 M€ in 2024.
Where is the headquarters of GLAXOSMITHKLINE BIOLOGICALS ?
The headquarters of GLAXOSMITHKLINE BIOLOGICALS is located in SAINT-AMAND-LES-EAUX (59230), in the department Nord.
Where to find the tax return of GLAXOSMITHKLINE BIOLOGICALS ?
The tax return of GLAXOSMITHKLINE BIOLOGICALS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does GLAXOSMITHKLINE BIOLOGICALS operate?
GLAXOSMITHKLINE BIOLOGICALS operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Drehen Sie Ihr Telefon ins Querformat, um das Diagramm anzuzeigen